ライフサイエンスコーパス: nonprogressor

1 maining four macaques remained asymptomatic (nonprogressors).

2 and did not progress to AIDS within 9-10 yr (nonprogressors).

3 in two well-defined groups (progressors vs. nonprogressors).

4 ith chronic HIV infection, and one long-term nonprogressor.

5 se mutations was found in more than a single nonprogressor.

6 volution patterns differ for progressors and nonprogressors.

7 in the minority of HIV-1-infected long-term nonprogressors.

8 ise periodically in HIV-1-infected long-term nonprogressors.

9 isit were both higher in progressors than in nonprogressors.

10 unodeficiency virus (HIV)-infected long-term nonprogressors.

11 attered over the CCR5 coding sequence from 8 nonprogressors.

12 tions was silent, and each was unique to two nonprogressors.

13 ent dynamics were similar in progressors and nonprogressors.

14 ower viral load compared with CCR5 wild-type nonprogressors.

15 nodeficiency virus type 1-infected long-term nonprogressors.

16 oviral therapy-treated patients or long term nonprogressors.

17 s of multiple phospholipids as compared with nonprogressors.

18 ienced liver disease progression and 23 were nonprogressors.

19 L most accurately identified progressors and nonprogressors.

20 red with both healthy controls and long-term nonprogressors.

21 ronic HIV-1-infected patients, and long-term nonprogressors.

22 racterized by a larger proportion of slow or nonprogressors.

23 surements in discriminating progressors from nonprogressors.

24 tiating progressors from normal subjects and nonprogressors.

25 risk scores to discriminate progressors from nonprogressors.

26 acute HIV-1 infection but not from long-term nonprogressors.

27 avoided for the majority of UC patients, the nonprogressors.

28 t much less frequently in aviremic long-term nonprogressors.

29 D onset and distinguish T1D progressors from nonprogressors.

30 adiographic progressors with 60 radiographic nonprogressors.

31 ronically HIV-infected individuals and elite nonprogressors.

32 than previously observed in adult long-term nonprogressors.

33 y virus infection as well as HIV-1 long-term nonprogressors.

34 icantly higher for progressors compared with nonprogressors (-0.72 mum/y vs. 0.14 mum/y; P = 0.004),

35 ial overlap between the two groups (range of nonprogressors, 0.10-1.7%).

36 higher in the progressors compared with the nonprogressors (12.52 +/- 2.71 versus 10.82 +/- 2.71; P

37 higher in the progressors compared with the nonprogressors (14.12 +/- 3.39 units/liter versus 12.62

38 rapid progressors to AIDS (24 patients) and nonprogressors (47 controls).

39 Progressors were significantly older than nonprogressors (70.6 versus 62.5 years; P < 0.001).

40 Long-term nonprogressor AD-18 has been infected with human immunod

41 Nonprogressors also had decreased BCHE activity over tim

42 The high proportion of long-term nonprogressors among chronic lymphocytic leukemia (CLL)

43 genotype was identified in 33 of 172 (19.2%) nonprogressors and 25 of 234 (10.7%) progressors from th

44 Methylation was assayed in 145 nonprogressors and 50 progressors using real-time quanti

45 progressors was readily separable from 15 UC nonprogressors and 6 normal controls.

46 ht to clarify the role of beta-chemokines in nonprogressors and AIDS patients by examination of beta-

47 CD4+ clones from nonprogressors and CD8+ clones from AIDS patients secret

48 Immunologic and genetic studies of long-term nonprogressors and exposed yet uninfected persons have h

49 Immunologic and genetic studies of long-term nonprogressors and exposed yet uninfected persons, as we

50 Both clinical nonprogressors and immunologically discordant progressor

51 omarkers can distinguish UC progressors from nonprogressors and improve cancer surveillance in UC.

52 patients but have been reported in long-term nonprogressors and in patients treated with highly activ

53 r results show that cocaine-using, long-term nonprogressors and normal progressors of HIV infection m

54 IGN compared with cocaine-nonusing long-term nonprogressors and normal progressors, respectively.

55 es (AUC) in differentiating progressors from nonprogressors and normal subjects were compared to the

56 of HIV-specific CD8+ T cells were present in nonprogressors and progressors, only those of nonprogres

57 ogous isolate than were sera from short-term nonprogressors and progressors.

58 gressive HIV disease compared with long-term nonprogressors and responders.

59 Lymphocytes from nonprogressors and seronegative controls also showed neg

60 Twenty biopsies from four UC nonprogressors and twenty-one biopsies from control indi

61 sequence (CCR5-Delta32) was found in 4 of 13 nonprogressors, and 12 different point mutations were fo

62 y more than two-fold between progressors and nonprogressors, and 12 miRs differed between late presen

63 nfection (clinical progressors), 10 clinical nonprogressors, and 3 immunologically discordant progres

64 HIV-1-infected long-term nonprogressors are a heterogeneous group of individuals

65 re their third birthday (>89%) and long-term nonprogressors are rare.

66 ed that these patients, as well as long-term nonprogressors, are infected with defective HIV-1 varian

67 llowed for 7-20 years (rapid progressors and nonprogressors), as well as a reference panel of normoal

68 gressors at corresponding visits or those of nonprogressors at any visit.

69 We further show that in a rare long-term nonprogressor, both an HIV-1-specific CD4(+)-T-cell clon

70 L2RA) did not differ between progressors and nonprogressors but were elevated in both groups relative

71 who had CD4 cell counts similar to those of nonprogressors but with a high likelihood of disease pro

72 years were compared between progressors and nonprogressors by Student's 2-tailed t-test.

73 ), while 265 children remained disease free (nonprogressors) by December 2011.

74 tion of both progressor (BALB) and long term nonprogressor (C57BL) mouse strains is characterized by

75 4 down-modulation, and a subset of long-term nonprogressors carry viruses defective in this function.

76 clinical progressors (CDR score, >/=0.5) and nonprogressors (CDR score, 0) and between APOE epsilon4

77 In comparison with HIV-positive nonprogressor chimpanzees, progressors have higher plasm

78 ific proliferative responses in the clinical nonprogressor cohort that correlated with significant nu

79 is increased among HIV-1- infected long-term nonprogressors compared with progressors; however, the h

80 eristics were not different in this group of nonprogressors compared with those with low AIRg who did

81 istance to ADA infection in CD4+ clones from nonprogressors could be partially reversed by treatment

82 differed significantly in progressors versus nonprogressors (DQB*0302, 42.6 vs. 34.7%, P = 0.0047; DQ

83 activity was observed in sera from long-term nonprogressors (elite controllers).

84 in CD4(+) T cells from HIV-1 elite long-term nonprogressors (eLTNPs), naive patients, and multiply ex

85 atients and discusses them in the context of nonprogressors enrolled in other cohorts.

86 y, B27- and B57-restricted CD8+ T cells from nonprogressors exhibited greater expansion than those re

87 se parameters from the progressors, the four nonprogressors exhibited more individual variability wit

88 utant identified in HIV-1-infected long-term nonprogressors failed to promote TERT destabilization.

89 sed genes was identified that distinguished "nonprogressors" from "progressors" with an estimated 100

90 Nonprogressors generally had high titers of ADCC Abs at

91 plantation biopsies were classified as IF/TA nonprogressors (group 1) or progressors (group 2) using

92 NS DNA in the at-risk progressor and at-risk nonprogressor groups followed for 4 years.

93 Although long-term survivor nonprogressors had a significantly higher percentage of

94 lin G (IgG) from rapid progressors, IgG from nonprogressors had no suppressive effects on glycoprotei

95 Patients defined as nonprogressors had significantly lower baseline levels o

96 d because genetic studies of long-term HIV-1 nonprogressors have associated specific HLA-B alleles wi

97 Long-term nonprogressors have high titer antibody responses to HIV

98 ) T cells in coinfected HLA-DR7(+) long-term nonprogressor HIV subjects with undetectable HCMV plasma

99 ells are elevated in blood of HIV+ long-term nonprogressors in comparison to HIV- donors.

100 a community-based cohort of HIV-2 long-term nonprogressors in rural Guinea-Bissau, we performed what

101 ressed, no difference was seen compared with nonprogressors in spine BMD, but hip BMD was modestly re

102 asia (UC progressors) from those without (UC nonprogressors), including assays of telomere length, an

103 r (P) and C57BL/10-H-2(k) (B10.BR) long-term nonprogressor (LTNP) mice.

104 in intestinal mucosal biopsies of long-term nonprogressor (LTNP) patients as compared to chronically

105 ation in elite controller (EC) and long-term nonprogressor (LTNP) patients has been associated with e

106 Long-term nonprogressors (LTNP) and seronegative controls had leve

107 Undiluted sera from long-term nonprogressors (LTNP) had broad neutralizing antibodies

108 lones from two progressors and two long-term nonprogressors (LTNP) in fetal thymic organ culture (FTO

109 -mediated control over HIV, termed long-term nonprogressors (LTNP) or elite controllers, and patients

110 A unique cohort of HIV-1-infected long term nonprogressors (LTNP) with normal CD4(+) T cell counts a

111 tetanus toxoid in normal controls, long-term nonprogressors (LTNP), and HIV-infected patients with pr

112 ed Rx <50) and untreated patients (long-term nonprogressors [LTNP]) matched for very low HIV RNA leve

113 jects; the latter group included 8 long-term nonprogressors (LTNPs) and 17 progressors.

114 ture by autologous CD8+ T cells in long-term nonprogressors (LTNPs) and in patients whose viremia was

115 Seven long-term nonprogressors (LTNPs) have been identified in a cohort

116 Long-term nonprogressors (LTNPs) of human immunodeficiency virus t

117 cation in rare individuals, termed long-term nonprogressors (LTNPs) or elite controllers.

118 V type 1-infected, untreated white long-term nonprogressors (LTNPs) with a cohort of 605 HIV-1-infect

119 an immunodeficiency virus (HIV) in long-term nonprogressors (LTNPs) with protective human leukocyte a

120 11 healthy donors, 360 +/- 69 in 3 long-term nonprogressors (LTNPs), 186 +/- 52 in 9 newly diagnosed

121 nts including typical progressors, long-term nonprogressors (LTNPs), and vertically HIV-infected subj

122 unodeficiency virus (HIV)-infected long-term nonprogressors (LTNPs), it is also present at the expect

123 t been evaluated in HIV-1-infected long-term nonprogressors (LTNPs), who maintain high CD4(+) T cell

124 True long-term nonprogressors (LTNPs)/elite controllers (ECs) maintain

125 a lack of disease progression (ie, long-term nonprogressors [LTNPs]) through 7 years of follow-up (LT

126 Here we tested long-term nonprogressors' (LTNPs') susceptibility to superinfectio

127 unodeficiency virus (SIV)-infected long-term-nonprogressor macaque.

128 Compared with the nonprogressor macaques, the two progressor macaques exhi

129 onprogressors and progressors, only those of nonprogressors maintained a high proliferative capacity.

130 ns with progressive disease, suggesting that nonprogressors may not target unique epitopes.

131 ral therapy (n = 21), HIV-infected long-term nonprogressors (n = 10), and HIV-seronegative volunteers

132 gressors had lower baseline FPIR values than nonprogressors (n = 270), with adjustments made for age

133 = 63), elite controllers (n = 19), long-term nonprogressors (n = 7), and HIV-infected patients affect

134 were stratified as progressors (n = 200) and nonprogressors (n = 751) and compared.

135 "Progressors" (N = 41) did not differ from "nonprogressors" (N = 156) in terms of hours per day spen

136 diagnosis with BE were matched to controls (nonprogressors, n = 291), for age, sex, and year of BE d

137 All others were considered nonprogressing (nonprogressors; n = 210 eyes).

138 Thus, in contrast to clinical nonprogressors, neither progressors nor immunologically

139 ere classified as progressors (P = F0/F1) or nonprogressors (NP = F3/F4) according to the severity of

140 were compared: eight progressors (P) and 45 nonprogressors (NP), using Cox proportional hazards mode

141 seen in HIV-1-infected cohorts of long-term nonprogressors or patients with AIDS.

142 Long-term nonprogressors or slow progressors may remain asymptomat

143 s/y in progressors versus -8,808 cells/y for nonprogressors (P < 0.001).

144 in progressors versus an increase of 0.6% in nonprogressors (P < 0.05).

145 brosis progressors compared with 20 fibrosis nonprogressors (P < 0.05).

146 nificantly over time between progressors and nonprogressors (P = .60), progressors had significantly

147 cells from PBMCs from HIV-positive long-term nonprogressors; partial blocking of infection with chemo

148 In studies of long-term nonprogressors - persons who have stable CD4+ T-cell cou

149 downregulation; how this contributes to the nonprogressor phenotype of these infected individuals re

150 rts of HIV-1-infected individuals: long-term nonprogressors, progressors to disease, acute seroconver

151 ogression and treatment, including long-term nonprogressors, progressors, and chronically infected su

152 apid progressors and nonrapid progressors or nonprogressors remained when longitudinal changes within

153 biopsy samples from long-term HIV-1-infected nonprogressors showed maintenance of normal CD4(+) T-cel

154 tion in Vif contributes significantly to the nonprogressor status of this mother and child.

155 decrease virus burden, whereas the long term nonprogressor strains do not.

156 esions from each of ten progressors and four nonprogressors suffering from longstanding UC.

157 mechanisms by which long-term HIV-1-infected nonprogressors suppress HIV-1 infection and maintain imm

158 differ between liver disease progressors and nonprogressors, the association of sCD14, I-FABP, and IL

159 In nonprogressors, the myopia progression at 1 year was les

160 , in a cohort of 33 HIV-1-infected long-term nonprogressors, those who were heterozygous for the muta

161 ort Study, enriched with rapid and long-term nonprogressors to increase statistical power.

162 ould be correctly assigned as progressors or nonprogressors using random sample cross-validation stat

163 However, IL-4 production in the nonprogressors was restricted to a limited number of p24

164 ost striking attribute of long-term survivor nonprogressors was the detection of HIV-1-specific CD4(+

165 dly, biologic clones from an adult long-term nonprogressor were noncytopathic in spite of similar lev

166 0.86 and in differentiating progressors from nonprogressors were 0.68 and 0.64, respectively; the AUC

167 The mean +/- SD ages of the progressors and nonprogressors were 64.2 +/- 7.8 years and 63.3 +/- 10.6

168 Progressors versus nonprogressors were compared using the two-sample t-test

169 These results indicated that nonprogressors were differentiated by increased prolifer

170 Clinical nonprogressors were found to respond to a wide range of

171 on to beta-chemokine production; clones from nonprogressors were poorly susceptible to ADA replicatio

172 The recent discovery of long term AIDS nonprogressors who harbor nef-attenuated HIV suggests th

173 We hypothesized that nonprogressors who were heterozygous for the mutant CCR5

174 An estimated 25-30% of long-term nonprogressors (who avoid clinical AIDS for 10 or more y

175 n progressors is limited compared to that of nonprogressors, who consistently maintain highly functio

176 mutant CCR5 gene might define a subgroup of nonprogressors with higher CD4+ T cell counts and lower

177 ere secreted when CD8 T cells from long-term nonprogressors with HIV-1 infection were stimulated.

178 udied including a unique cohort of long-term nonprogressors with low levels of plasma viral RNA and s

179 tion favoring nonsynonymous mutations, while nonprogressors with low viral loads selected against the

180 cificity for distinguishing progressors from nonprogressors with optimum choice of threshold.

181 e were indistinguishable from CCR5 wild-type nonprogressors with regard to all measured immunologic a

182 c CD8+ T cells were not limited to long-term nonprogressors with restriction of plasma virus.

183 Furthermore, long-term nonprogressors with the wild-type CCR5 genotype are indi

184 cer/dysplasia and/or aneuploidy) compared to nonprogressors (without cancer/dysplasia/aneuploidy), wh